Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
- The US generics market had total revenues of $69.9 billion in 2022, representing a compound annual growth rate (CAGR) of 2.2% between 2017 and 2022.
- Market consumption volume increased with a CAGR of 0.3% between 2017 and 2022, to reach a total of 91.4 % in 2022.
- 9 out of 10 prescriptions written in the United States, according to the FDA, are for generic drugs. Increased access to generic drugs encourages market competition, which lowers the cost of treatment and broadens access to healthcare for more patients.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts
Reasons to Buy
- What was the size of the United States generics market by value in 2022?
- What will be the size of the United States generics market in 2027?
- What factors are affecting the strength of competition in the United States generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the United States's generics market?
Table of Contents
1 Executive Summary
2 Market Overview
3 Market Data
4 Market Segmentation
5 Market Outlook
6 Five Forces Analysis
7 Competitive Landscape
8 Company Profiles
9 Macroeconomic Indicators
10 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Teva Pharmaceutical Industries Limited
- Viatris Inc.
- Pfizer Inc.
- Novartis AG
